302 related articles for article (PubMed ID: 28938468)
21. Nonfunctional pancreatic endocrine tumor in the peripancreatic region in a Chinese patient with multiple endocrine neoplasia type 1.
Wang BP; Tian WJ; Zhang J; Jiang CX; Qu HQ; Zhu M
J Int Med Res; 2018 Feb; 46(2):908-915. PubMed ID: 29239255
[TBL] [Abstract][Full Text] [Related]
22. Predicting the risk of multiple endocrine neoplasia type 1 for patients with commonly occurring endocrine tumors.
de Laat JM; Tham E; Pieterman CR; Vriens MR; Dorresteijn JA; Bots ML; Nordenskjöld M; van der Luijt RB; Valk GD
Eur J Endocrinol; 2012 Aug; 167(2):181-7. PubMed ID: 22581216
[TBL] [Abstract][Full Text] [Related]
23. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
[TBL] [Abstract][Full Text] [Related]
24. No Association of Blood Type O With Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.
Nell S; van Leeuwaarde RS; Pieterman CR; de Laat JM; Hermus AR; Dekkers OM; de Herder WW; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IH; Vriens MR; Valk GD
J Clin Endocrinol Metab; 2015 Oct; 100(10):3850-5. PubMed ID: 26247473
[TBL] [Abstract][Full Text] [Related]
25. [Surgery for pancreatic neuroendocrine tumors].
Shibata C; Egawa S; Motoi F; Morikawa T; Naitoh T; Unno M; Sasaki I
Nihon Geka Gakkai Zasshi; 2012 Nov; 113(6):502-6. PubMed ID: 23330458
[TBL] [Abstract][Full Text] [Related]
26. Rupture of small cystic pancreatic neuroendocrine tumor with many microtumors.
Sagami R; Nishikiori H; Ikuyama S; Murakami K
World J Gastroenterol; 2017 Oct; 23(37):6911-6919. PubMed ID: 29085235
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome.
Dʼsouza SL; Elmunzer BJ; Scheiman JM
J Clin Gastroenterol; 2014; 48(5):458-61. PubMed ID: 24356459
[TBL] [Abstract][Full Text] [Related]
28. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.
Ito T; Igarashi H; Uehara H; Berna MJ; Jensen RT
Medicine (Baltimore); 2013 May; 92(3):135-181. PubMed ID: 23645327
[TBL] [Abstract][Full Text] [Related]
29. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.
Soczomski P; Jurecka-Lubieniecka B; Krzywon A; Cortez AJ; Zgliczynski S; Rogozik N; Oczko-Wojciechowska M; Pawlaczek A; Bednarczuk T; Jarzab B
Front Endocrinol (Lausanne); 2021; 12():681013. PubMed ID: 34122352
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.
Sadowski SM; Pieterman CRC; Perrier ND; Triponez F; Valk GD
Endocr Relat Cancer; 2020 Jun; 27(6):R145-R161. PubMed ID: 32229700
[TBL] [Abstract][Full Text] [Related]
31. Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort.
van Beek DJ; Verkooijen HM; Nell S; Bonsing BA; van Eijck CH; van Goor H; Hoogwater FJH; Nieveen van Dijkum EJM; Kazemier G; Dejong CHC; Brosens LAA; Wessels FJ; Borel Rinkes IHM; Valk GD; Vriens MR
Neuroendocrinology; 2021; 111(8):705-717. PubMed ID: 32721974
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
Sallinen V; Haglund C; Seppänen H
Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
[TBL] [Abstract][Full Text] [Related]
33. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.
Bartsch DK; Slater EP; Albers M; Knoop R; Chaloupka B; Lopez CL; Fendrich V; Kann PH; Waldmann J
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2387-91. PubMed ID: 25210877
[TBL] [Abstract][Full Text] [Related]
34. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.
Fahrmann JF; Wasylishen AR; Pieterman CRC; Irajizad E; Vykoukal J; Murage E; Wu R; Dennison JB; Krishna H; Peterson CB; Lozano G; Zhao H; Do KA; Halperin DM; Agarwal SK; Blau JE; Del Rivero J; Nilubol N; Walter MF; Welch JM; Weinstein LS; Vriens MR; van Leeuwaarde RS; van Treijen MJC; Valk GD; Perrier ND; Hanash SM
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4969-e4980. PubMed ID: 34318891
[TBL] [Abstract][Full Text] [Related]
35. [Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms].
Couvelard A; Scoazec JY
Ann Pathol; 2020 Apr; 40(2):120-133. PubMed ID: 32035641
[TBL] [Abstract][Full Text] [Related]
36. Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study.
Tamagno G; Scherer V; Caimo A; Bergmann SR; Kann PH
Digestion; 2018; 98(2):112-118. PubMed ID: 29698969
[TBL] [Abstract][Full Text] [Related]
37. Precision radiotherapy using MR-linac for pancreatic neuroendocrine tumors in MEN1 patients (PRIME): a protocol for a phase I-II trial, and systematic review on available evidence for radiotherapy of pNETs.
van Vliembergen ENM; Eijkelenkamp H; Valk GD; Vriens MR; Meijer GJ; Intven MPW; de Laat JM
Front Endocrinol (Lausanne); 2023; 14():994370. PubMed ID: 37305036
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.
Nuñez JE; Donadio M; Filho DR; Rego JF; Barros M; Formiga MN; Lopez R; Riechelmann R
J Gastrointest Oncol; 2019 Aug; 10(4):645-651. PubMed ID: 31392045
[TBL] [Abstract][Full Text] [Related]
39. Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome.
Pieterman CR; Schreinemakers JM; Koppeschaar HP; Vriens MR; Rinkes IH; Zonnenberg BA; van der Luijt RB; Valk GD
Clin Endocrinol (Oxf); 2009 Apr; 70(4):575-81. PubMed ID: 18616711
[TBL] [Abstract][Full Text] [Related]
40. Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1.
Yates CJ; Newey PJ; Thakker RV
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):895-905. PubMed ID: 26165399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
